Results 241 to 250 of about 3,216,105 (293)

Polymeric prodrugs, 5. Dextran‐bound antirheumatic agent naproxen

Die Makromolekulare Chemie, 1986
AbstractThe dextran‐bound antirheumatic agent, Naproxen [(+)‐2‐(6‐methoxy‐2‐naphtyl)propionic acid] (3) was synthesized by linking the 2‐aminoethyl ester of Naproxen to the oxydized dextran via an alkylamine bond. The hydrolytic stabilities of modified dextrans were examined viscometrically. The drug release from polymeric prodrug samples containing 68–
Mária Azori, János Pató, Éva Csákvári, Ferenc Tüdős   +3 more
openaire   +2 more sources

[Nonsteroidal antirheumatic agents and the gastrointestinal system].

Reumatizam, 1990
The antiinflammatory drugs are broadly used also in the treatment of inflammatory and degenerative rheumatic diseases relating to the treatment of extraarticular rheumatism. It has been held that they have an effect in rheumatic diseases even by means of the inhibition of prostaglandins synthesis.
openaire   +2 more sources

Antimalarial agents compared with or in combination with other disease-modifying antirheumatic drugs

The American Journal of Medicine, 1988
Available published comparisons of antimalarial drugs with other disease-modifying antirheumatic drugs (DMARDs) are reviewed, as well as reports of combinations of DMARDs, in the treatment of rheumatoid arthritis and juvenile rheumatoid arthritis.
openaire   +3 more sources

Therapeutics of Antirheumatic Agents

American Journal of Health-System Pharmacy, 1980
Eric Boyce, Ronald P. Evens
openaire   +3 more sources

Antiallergic Activity of Detergent and Antirheumatic Agents

International Archives of Allergy and Immunology, 1964
Y. Mizushima, R. Kasukawa
openaire   +3 more sources

Comparison of Serious Adverse Event Profiles Among Antirheumatic Agents Using Japanese Adverse Drug Event Report Database

Therapeutic Innovation and Regulatory Science, 2018
Yomei Matsuoka, M. Narukawa
semanticscholar   +1 more source

Safety of disease-modifying antirheumatic drugs and biologic agents for rheumatoid arthritis patients in real-life conditions.

Seminars in Arthritis & Rheumatism, 2015
L. Abasolo, L. León, L. Rodríguez-Rodríguez, A. Tobías, Z. Rosales, Jose Maria Leal, V. Castaño, C. Vadillo, P. Macarrón, O. Fontsere, J. Jover   +10 more
semanticscholar   +1 more source

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis

Annals of the Rheumatic Diseases, 2010
Carine Salliot, A. Finckh, W. Katchamart, Yan Lu, Ye Sun, C. Bombardier, E. Keystone   +6 more
semanticscholar   +1 more source

Studies on type II collagen-induced polyarthritis in rats. Effect of antiinflammatory and antirheumatic agents.

Arthritis & Rheumatism, 1981
A. Sloboda, J. Birnbaum, A. Oronsky, S. Kerwar   +3 more
semanticscholar   +1 more source

Characterization of pristane-induced arthritis, a murine model of chronic disease: response to antirheumatic agents, expression of joint cytokines, and immunopathology.

Arthritis & Rheumatism, 2004
C. Patten, K. Bush, I. Rioja, R. Morgan, P. Wooley, J. Trill, P. Life   +6 more
semanticscholar   +1 more source